AI assistant
Bio Green Med Solution, Inc. — Director's Dealing 2024
Jan 31, 2024
35092_dirs_2024-01-31_c03c1f0b-5298-4b13-adc6-e656bfe36b5c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cyclacel Pharmaceuticals, Inc. (CYCC)
CIK: 0001130166
Period of Report: 2024-01-29
Reporting Person: SCHWARTZ BRIAN (Director, Interim Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-01-29 | Common Stock | A | 12500 | — | Acquired | 15205 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-01-29 | Stock Option (right to buy) | $2.28 | A | 12500 | Acquired | 2034-01-29 | Common Stock (12500) | Direct |
Footnotes
F1: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal monthly installments beginning on February 29, 2024, subject to the Reporting Person's continued service through the applicable vesting date.
F2: These securities were granted to Dr. Schwartz in connection with his appointment as interim Chief Medical Officer of Cyclacel Pharmaceuticals, Inc.
F3: The shares underlying the option vest in equal monthly installments beginning on February 29, 2024, subject to the Reporting Person's continued service through the applicable vesting date.